

REMARKS

Claims 30, 32, and 34 have been amended to recite type 2 diabetes and rewritten in independent format, the support for which can be found throughout the specification and claims, e.g., paragraph [0034] and claim 20. Claim 32 has been amended to substitute "preventing" with "inhibiting", the support for which can be found in, for example, Example B. New claims 36-39 depend from claim 30; new claims 40-43 depend from claim 32; and new claims 44-47 depend from claim 34, the support for which can be found throughout the specification, e.g., in original claims 21-24. Claims 31, 33, and 35 have been cancelled rendering moot the rejections of these claims. No new matter has been added. Thus, entry of the amendment is respectfully requested.

Information Disclosure Statement (IDS)

Initially, with respect to the IDS, Applicant submits herewith as Exhibits A and B, the two outstanding non-patent literature publications, corresponding to the abstract of Japanese application JP61167622 (Exhibit A) and to pages 370-377 of the textbook *Yeast Technology* (Exhibit B).

Claim Objections

The Patent Office has objected to claims 30, 32, and 34 for containing the claim recitation "cell walls of yeast of the genus *Saccharomyces cerevisiae*" on grounds that *Saccharomyces cerevisiae* is a species, not a genus. As suggested by the Examiner, claims 30, 32, and 34 have been amended to recite "cell walls of yeast of the species *Saccharomyces cerevisiae*". Accordingly, the rejection has been rendered moot and withdrawal is requested.

35 U.S.C. § 112, first paragraph

Claims 32-33 have been rejected for failing to comply with the enablement requirement. The Patent Office has taken

the position that "the term 'prevent' is an absolute definition which means to stop from occurring and, thus, requires a higher standard for enablement than does 'treating'." The rejection as to claim 33 is moot. Applicant respectfully traverses with respect to claim 32.

Claim 32 has been amended to delete the recitation "preventing" and to include the recitation "inhibiting." The support for inhibiting type 2 diabetes can be found throughout the specification, for example, in Example 2 at paragraphs [0089] - [0096]. Here, a patient diagnosed with diabetes was administered the composition in accordance with the methods of the invention. Even after breaches of the patient's prescribed diet, which included the consumption of chocolate, the method of the instant invention inhibited the expected rise in the blood glucose level after eating the high-sugar meal, thereby inhibiting post-prandial hyperglycemia. Accordingly, the specification clearly provides enablement for a method of inhibiting hyperglycemia in a subject with type 2 diabetes, as recited in claim 32. Accordingly, withdrawal of the rejection is respectfully requested.

35 U.S.C. § 112, second paragraph

Claims 30-35 have been rejected as being indefinite. The Patent Office has taken the position that the claims fail to particularly point out and distinctly claim the subject matter which Applicant regards as the invention. Claims 31, 33, and 35 have been cancelled rendering moot the rejections as to these claims. Applicant respectfully traverses with respect to claims 30, 32, and 34.

In the Examiner's view, the phrase "a total glucan and mannan content of at least 34% by mass," is unclear. The claim has been amended to replace the offending language with "a total content of both glucans and mannans." Accordingly, the rejection

has been rendered moot and withdrawal is respectfully requested.

35 U.S.C. § 102(b)

Claims 30 and 34 have been rejected for allegedly being anticipated. The Office's position is that the reference *Jamas et al.*, U.S. Patent 4,962,094 ("Jamas") discloses compositions of β -glucans and methods of using same for many possible reasons, such as a source of dietary fiber, a stool or fecal bulking agent, or for improving digestion and, therefore, would be administered to a human subject. The Office concludes that *Jamas* inherently anticipates claims 30 and 34, because "the population of subjects for each of the claimed methods would be the same population as the population to which the composition of *Jamas* would be administered." Applicant respectfully traverses.

Turning to the specific allegations set forth in the Official action on pages 6-7, Applicant submits that the Office has failed to carry its burden to prove a *prima facie* case that claims 30 and 34 are inherently anticipated. The Office has not advanced any evidence or reasoning substantiating its position that the claims are inherently anticipated, and thus, the Office has not met its burden.

The M.P.E.P. § 2112 requires that an Examiner "[i]n relying upon the theory of inherency, ... must provide a basis in fact and/or technical reasoning to reasonably support the determination that the allegedly inherent characteristic necessarily flows from the teachings of the applied prior art." *Ex parte Levy*, 17 U.S.P.Q.2d 1461, 1464 (Bd. Pat. App. & Inter. 1990) (emphasis in original). To establish inherency, the extrinsic evidence must make clear that the missing descriptive matter is necessarily present in the thing described in the

reference, and that it would be so recognized by persons of ordinary skill. Inherency, however, may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient to establish the inherency of the result or characteristic. *In re Robertson*, 49 U.S.P.Q.2d 1949, 1950-51 (Fed. Cir. 1999) (emphasis added). Thus, to maintain a rejection for a *prime facie* case of inherency, the Patent Office has the initial burden of providing evidence or a rationale proving beyond a mere probability or possibility that the population of subjects for each of the claimed methods would in fact be the same population as the population to which the composition of *Jamas* would be administered. Here, that burden has not been met.

The text of the rejection is merely directed to factual allegations that the population of subjects having digestive disorders is the same population as those having type 2 diabetes. Accordingly, the Office has not offered any evidence or reasoning to support its conclusions, and thus, has not met its burden to sustain this ground of rejection.

35 U.S.C. § 103(a)


Claims 30-31 and 34-35 are rejected as being obvious over the *Jamas* in view of *Wursch et al.* (Diabetes Care, 1997) [hereinafter "*Wursch*"]. The Patent Office has taken the position that *Jamas* teaches the use of compositions based on whole β -glucans for the treatment of dietary disorders, and as dietary additives for providing a source of fiber, but it does not teach the specific administration of the composition to subjects with type II diabetes. In the Examiner's view, *Wursch* teaches that "diabetic individuals should benefit from diets that are high in soluble fiber beta-glucan." Thus, the Examiner

contends that it would have been obvious to combine the references to arrive at the claimed invention. The rejection as to claims 31 and 35 is moot. Applicant respectfully traverses with respect to claims 30 and 34.

The collective teaching of *Jamas* and *Wursch* do not provide any rationale for treating hyperglycemia or for stabilizing glycemia by administering the claimed composition to a subject with type 2 diabetes. First, the principal reference - *Jamas* - *inter alia*, does not teach the specific administration of the agent to subjects with type 2 diabetes. Its combination with the secondary reference - *Wursch* - does not cure this deficiency and actually teaches away from the claimed invention.

Wursch generally teaches the potential interest of soluble fibers (see abstract, page 1774, 3rd column, §4), and more specifically of grain (in particular barley or oats) β -glucans (see sentence bridging pages 1774 and 1775, in which only β -glucans for oats and barley are discussed), for reducing hyperglycemia of diabetic patients. Thus, *Wursch* does not teach the use of yeast β -glucans of the species *Saccharomyces cerevisiae* as recited in claims 30 and 34.

Structurally, grain and yeast β -glucans are distinct compounds. Indeed, barley or oats, and more generally grain, β -glucans are (1,3)(1,4) β -glucans (see *Wursch*, page 1775, 1st sentence), while yeast β -glucans are (1,3)(1,6) β -glucans. This structural distinctiveness is illustrated below:

Linear grain (1,3)(1,4) β -glucansBranched yeast (1,3)(1,6) β -glucans

In addition, these structural differences result in distinct physical properties (see enclosed herein WO2006/015627, page 3, §3 [Exhibit C]). Specifically, Wursch discloses that grain (1,3)(1,4) β -glucans are soluble in water (this is confirmed in WO2006/015627, see page 3, paragraph under the chemical formula). Yeast (1,3)(1,6) β -glucans, which are present in the agent administered according to the invention, are not soluble in water. Yeast (1,3)(1,6) β -glucans are prepared by collecting the insoluble fraction after yeast hydrolysis. In fact, the difference in water solubility results in a difference in the viscosity between soluble grain and insoluble yeast β -glucans. Indeed, soluble grain (1,3)(1,4) β -glucans have viscosifying properties (see Wursch, page 1775, lines 3-7 and WO2006/015627, page 2, 3rd line from the end through page 3, line 2), which are believed to be involved in their efficiency for reducing hyperglycemia in diabetic patients (see Wurcsh, page 1775, middle column, last paragraph). In contrast, due to its low solubility in water, yeast (1,3)(1,6) β -glucans do not have comparable viscosifying properties (see WO2006/015627, page 3, §3). Thus, a person of ordinary skill in the art would not have looked to yeast (1,3)(1,6) β -glucans to have the same hyperglycemia-reducing properties as the

(1,3)(1,4) β -glucans of Wursch. Indeed, the results were unexpected.

Moreover, since the particular viscosifying properties of grain (1,3)(1,4) β -glucans, which are disclosed to be the cause of the hyperglycemia-reducing effect [see Wurcsh, page 1775, middle column] and are not shared by yeast (1,3)(1,6) β -glucans, a skilled artisan would not have looked to yeast(1,3)(1,6) β -glucans of the species *Saccharomyces cerevisiae* for treating hyperglycemia or stabilizing glycemia in a subject with type 2 diabetes. Accordingly, withdrawal of the rejection is respectfully requested.

As it is believed that all of the rejections set forth in the Official Action have been fully met, favorable reconsideration and allowance are earnestly solicited.

If, however, for any reason the Examiner does not believe that such action can be taken at this time, it is respectfully requested that he/she telephone applicant's attorney at (908) 654-5000 in order to overcome any additional objections which he might have.

If there are any additional charges in connection with this requested amendment, the Examiner is authorized to charge Deposit Account No. 12-1095 therefor.

Dated: April 28, 2008

Respectfully submitted,

By

Stephen J. Brown

Registration No.: 43,519

LERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

EXHIBIT A

DIABETES-CONTROLLING AGENT

Publication number: JP61167622
Publication date: 1986-07-29
Inventor: AKAZAWA YOSHIATSU
Applicant: ASAHI BREWERIES LTD
Classification:
- international: A61K36/06; A61P3/08; A61P3/10; A61K36/06;
A61P3/00; (IPC1-7): A61K35/72
- European:
Application number: JP19850010264 19850122
Priority number(s): JP19850010264 19850122

[Report a data error here](#)

Abstract of JP61167622

PURPOSE:To use cell wall component of beer yeast as a diabetes-controlling agent containing a large amount of food fiber. CONSTITUTION:It has been found that the cell wall of beer yeast is rich in vitamins and minerals, contains 25% crude protein and 50.4% food fiber such as glucan, mannan, etc., and is effective as a fiber diet for controlling diabetes. The beeryeast cell wall is obtained by contacting fresh beer yeast produced by Asahi Beer Co, with a sodium hydroxide solution of 10pH for 50sec to remove the bitter taste, washing with water, letting stand at 50-70 deg.C for >=2hr to effect the autodigestion, and extracting and removing the solubilized component with water. The obtained powder is tableted to a tablet of 243.75mg weight. Daily administration of 30 tablets of the beer yeast corresponds to about 3.5g of food fiber. Improvement in GTT, in renal function such as lowering of HbA value, and hyperlipemia accompanied by diabetes has been confirmed.

Data supplied from the esp@cenet database - Worldwide

EXHIBIT B

YEAST TECHNOLOGY

Second Edition

Gerald Reed

Universal Foods Corporation
Milwaukee, Wisconsin

Tilak W. Nagodawithana

Universal Foods Corporation
Milwaukee, Wisconsin

An Avi Book

Published by Van Nostrand Reinhold
New York

To our wives, Helen (*in memoriam*) and Swarna

An AVI Book
(AVI is an imprint of Van Nostrand Reinhold)

Copyright © 1991 by Van Nostrand Reinhold
Library of Congress Catalog Card Number 90-33144
ISBN 0-442-31892-8

All rights reserved. No part of this work covered by the copyright hereon
may be reproduced or used in any form by any means—graphic,
electronic, or mechanical, including photocopying, recording, taping, or
information storage and retrieval systems—without written permission
of the publisher.

Printed in the United States of America.

Van Nostrand Reinhold
115 Fifth Avenue
New York, New York 10003

Van Nostrand Reinhold International Company Limited
11 New Fetter Lane
London EC4P 4EE, England
Van Nostrand Reinhold
480 La Trobe Street
Melbourne, Victoria 3000, Australia

Nelson Canada
1120 Birchmount Road
Scarborough, Ontario M1K 5G4, Canada

16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

Library of Congress Cataloging-in-Publication Data
Reed, Gerald.
Yeast technology/Gerald Reed, Tilak W. Nagodawithana.—2nd ed.
p. cm.
“An AVI book.”
Includes bibliographical references.
ISBN 0-442-31892-8

1. Yeast. I. Nagodawithana, Tilak W. II. Title.
TP580.R43 1991
664'.68—dc20
90-33144

brewing industry, the spent yeast generated was far in excess of what the bakers could use for their baking. The brewers then began to experience the problem of excess yeast disposal which accounted for a substantial proportion of their waste load. As a means of disposal, the spent yeast was often sprayed on agricultural lands as a source of fertilizer.

Toward the end of the nineteenth century, several studies demonstrated the importance of yeast as a nutritional supplement for both animals and humans, primarily due to its high level of protein. More recent studies have indicated the importance of brewer's yeast as an excellent source of the vitamin B complex. Many major brewers who saw an opportunity following these findings began an extensive search to produce products of greater commercial value to maximize their overall profitability.

Pioneering efforts made in England and Germany led to the development of a variety of nutritional and flavoring agents derived from brewer's yeast to meet the needs of the food industry. Continued research in this area during the last few decades led to the commercialization of several other products derived from both baker's and brewer's yeast. The major yeast-derived products of commercial importance are listed as follows: (1) flavor products and flavor enhancers, (2) products of nutritional value, (3) colorant, (4) enzymes, and (5) products of pharmaceutical and cosmetic value.

FLAVOR PRODUCTS AND FLAVOR ENHANCERS

Yeast Extracts

Yeast extracts are commercially available as a powder or paste and have been used extensively by the food industry as a flavoring agent. It is a concentrate of the soluble fraction of yeast generally made following autolysis, which is essentially a degradation process carried out by activating the yeast's own degradative enzymes to solubilize the cell components found within the cell. Yeast extracts can also be made by hydrolysis using external reagents or enzymes capable of releasing the cell content in a highly degraded form. Yeast extracts have received wide acceptance in the food industry during the last few decades as a natural flavoring agent. They are also cost-effective in relation to other flavoring agents (which are often not natural) on the basis of equivalent flavor intensity. They are used extensively in the fermentation industry and as a complex nutritional source in the preparation of microbiological growth media for plate assays. The production of yeast extracts worldwide amounts to approximately 35,000 tons. In general, since the surplus yeast in the brewing industry is relatively cheap, it is utilized extensively in the production of extracts to meet the

needs of the food and fermentation industries. Extracts made from the primary-grown yeast such as *Saccharomyces cerevisiae* (baker's), *Candida utilis*, or *Kluyveromyces marxianus* have flavor profiles somewhat different from those of brewer's yeast. Nevertheless, they have unique flavor characteristics and are widely used as flavoring agents in the food industry.

Although brewer's yeast is available in large quantities at a relatively cheap price, it is likely to contain undesirable flavor characteristics as a result of the carryover of hop resins and beer solids from the brewery fermentation. The hop resins, which are often bitter, are primarily humulones and isohumulones present as beer solids or as compounds firmly adsorbed to the surface of the yeast cells. Further processing of this yeast cream requires a debittering step that is sometimes wasteful and often costly. A partial debittering is less costly and makes the final extract less bitter, often providing a beneficial effect to the overall flavor profile. In contrast, primary-grown yeast is more costly compared to brewer's yeast and the products are also priced higher in view of the higher raw material cost. Because of their unique flavor characteristics, such extracts are capable of imparting an overall flavor to a food formulation.

Different types of yeast extracts commercially available for food use differ from each other with respect to their flavor profiles. There are several factors that influence such quality differences and these may include the type and the condition of the yeast, presence of extraneous matter, conditions used in the extraction and processing of yeast solubles, and level of bacterial contamination during processing.

Autolysis, which is essentially an autodigestion of the yeast, requires the mediation of several endogenous enzymes. These enzymes, generally compartmentalized within the living cell, are located in the general matrix of the cell. Conditions that cause cell death also cause inactivation of the endogenous degrading enzymes, thereby making the cell less sensitive to further autolytic activity. Hence, a high viability in the yeast is a prerequisite for maximum autodegradation during an autolysis.

The flavor of the final product is also influenced by the extraneous matter present in the yeast slurry, which is often the case when the substrate used in the process is spent brewer's or distiller's yeast. Generally, well-washed baker's yeast produces an extract that is more bland than the one made from an inadequately washed molasses-grown yeast. This phenomenon is also seen in the production of extracts of *K. marxianus* grown on whey permeate. For this reason, some molasses is incorporated during processing of *K. marxianus* extracts to bring out the desired meaty-flavor notes. Likewise, the level of bitter components introduced from brewer's spent yeast to the process can have a profound influence on the quality of the final product.

Some food manufacturers do not like

ness in the extracts they wish to use in their formulations. The presence of such flavor compounds enable them to generate desirable reaction flavors so important for improving the product quality. The bitterness level in the final extract can generally be controlled by the level of efficiency of the initial cleaning of the spent brewer's yeast. An alkaline wash is sometimes applied to develop a less bitter flavor in the final product even though such a treatment reduces the final extract yield. Contamination is common during extract production, but it is generally controlled at a low level either by control of process conditions or by use of certain antimicrobial agents. Commercial extracts must meet certain microbiological specifications before they can be sold for food applications.

Detailed manufacturing procedures for the production of various types of extracts are not well documented due to obvious reasons. Nevertheless, the basic operational steps currently in use by most extract manufacturers are cleaning of the yeast if it is a by-product of another industry; solubilization; separation of solubles from the digested material; clarification; concentration; and drying.

Primary-grown yeast requires an appropriate wash to remove the mother liquor, especially if grown on molasses. Brewer's yeast, which is extensively used in the industry, must be highly viable at the time of processing and should contain a minimal level of microbial contaminants, hop resins, trub, and other undesirable soluble or particulate matter. The trub and other insoluble matter are separated by passing the cream through a 150-200 μ vibrating mesh. A variety of bitter components added as hops at the early stages of the brewing process can be detected in the spent yeast cream either in the soluble fraction as beer solids or as compounds adsorbed to the yeast cell wall. The latter, if not removed at the initial cleaning operation, may be released into the extract medium during autolysis, imparting a bitter flavor to the final product.

These hop resins present on the surface of the yeast cell can, however, be solubilized by an alkaline wash. Due to the variability in quality of brewer's yeast at different brewery locations as a result of their minor variations in processing, some level of blending of different-quality yeasts is necessary to maintain consistency of the final products. There are three distinct manufacturing practices for the production of yeast extracts: autolysis, plasmolysis, and hydrolysis.

Autolysis

All macromolecules present in viable yeast cells are held back within the cell by the semipermeable membrane. The cell wall provides the mechanical support necessary to maintain the size and shape of the cell. Autolysis is

a process by which the cell components are solubilized by activation of the degradative enzymes inherently present within the cell. It is achieved by the application of carefully controlled conditions such as temperature, pH, time, and addition of certain enhancing agents. Such conditions bring death to the yeast population without inactivating the degrading enzymes that remain compartmentalized in a live cell. Under these conditions, important enzyme systems responsible for carrying out regular metabolism are no longer governed by the delicate control mechanisms that exist in a healthy living cell. Death causes disorderliness within the cell, allowing the free degradative enzymes to indiscriminately attack their specific substrates. This attack causes the breakdown of the corresponding macromolecules like proteins and nucleic acids to their basic units that are soluble by nature. Disorderliness within the cell results in a leaky cell wall and a loss in the integrity of the semipermeable membranes and permits the soluble components to leak out of the cell into the surrounding environment. The final flavor profile and the extract yield in a well-controlled process are largely dependent on the temperature; pH; duration; viability; and concentration of yeast; and type of solubilizing aids used in the process. Some conditions that favor higher extract yields may not necessarily favor the production of extracts with the desirable flavor. A substantial amount of research effort is thus necessary to optimize conditions so that the product has the desired flavor profile.

Common solubilizing aids used during autolysis are most often enzymes that are proteases, glucanases, nucleases, or phosphodiesterases. Ethyl acetate is often used to enhance autolysis and also to control the contaminants to the minimum. Proteases, such as papain, are known to increase extract yield only in longer autolysis procedures as practiced in the United States, United Kingdom, and Australia. Their effect is minimal when the duration of autolysis is shorter than 20 hours as practiced in Japan and France.

The autolysis procedure is well suited for the production of low-sodium yeast extracts that are gaining wide acceptance in the food industry. Although these extracts taste bland, they have the capability of improving the flavor profile by combining with other food ingredients. Low-sodium yeast extracts are becoming increasingly important components of convalescent and infant food formulations.

Autolysis, or self-digestion, of viable yeast cells takes place at an acceptable pace when the yeast slurry of approximately 15% solids is maintained at 45-50°C for 24-36 hours at a pH of about 5.5. The lysis of these live whole cells is primarily due to the action of $\beta(1-3)$ glucanase and protease enzymes present within the cells. The $\beta(1-6)$ glucanase and mannanase enzymes participate in the further solubilization of the wall matrix. More than 40 proteolytic enzymes have been identified to date in

Saccharomyces cerevisiae of which only a few enzymes can be described as important in the autolytic process. Four of the important proteolytic enzymes that play a major role during lysis are proteinase ysc A, proteinase ysc B, carboxypeptidase ysc Y, and carboxypeptidase ysc S. All four of these soluble proteolytic enzymes appear to be localized in the vacuole whereas their inhibitors are in the cytoplasm outside the vacuole (Table 8-1). Such a compartmentalization segregates biologically compatible components to allow the control and integration of the intracellular activities for the orderly functioning of a viable system.

Under autolytic conditions the yeast cells begin to die after all the cell reserves have been used up. This condition, then, can bring about a disorderliness within the yeast cell, thus marking the beginning of the autolysis process. There is a gradual breakdown of barriers in the highly compartmentalized cell matrix with the release of proteolytic enzymes from the vacuole into the degenerating cell matrix. These enzymes are, at first, inactivated due to the formation of complexes by reacting with corresponding inhibitors present in the immediate vicinity. This inactivation was evident when proteinase ysc A and proteinase ysc B were extracted by autolysis at pH 7. However, incubation of the yeast extracts at pH 5 caused reactivation of these proteinase enzymes (Hata, Hayashi, and Doi and Dalbec 1969; Saheki and Holzer 1975).

Addition of purified proteinase ysc A to fresh crude yeast extracts also accelerated the inactivation of the proteinase ysc B inhibitor and the appearance of maximal activity of proteinase ysc B and carboxypeptidase ysc Y. Their existence is thus reflected by a proteolytically degradable inhibitor of the proteinases that impart minimal influence in the long run on the proteolytic enzymes under conditions conducive for autolysis (pH 5.5; temperature 45°-55°C).

The vacuolar proteinases, like proteinase ysc A, proteinase ysc B, carboxypeptidase ysc Y, carboxypeptidase ysc S, and aminopeptidases are involved in highly nonspecific protein and peptide degradation. No other function has been attributed to vacuolar proteolytic enzymes to date. Under natural conditions, these enzymes most likely provide the living cell the ability to maintain an amino acid pool in the vacuole at the expense of the unneeded cell proteins for new protein synthesis. Under autolytic conditions, these enzymes provide the necessary proteolytic degradation by indiscriminately attacking the proteins present in the cytoplasmic matrix. Likewise, the nucleases present in the cell begin to act on the RNA and DNA, reducing them to polynucleotides, mononucleotides, and nucleosides. These soluble components of low molecular weight should finally be released to the surrounding medium.

Table 8-1. Properties of Yeast Proteases

| Type | Proteinase ysc A | Proteinase ysc B | Carboxypeptidase ysc Y | Carboxypeptidase ysc S | Optimum pH | Cell location | Molecular weight | Inhibitors | Isoelectric pt. | Optimum T (°C)* |
|------|--------------------|----------------------|------------------------|------------------------------------|------------|---------------|------------------|-------------------------|-----------------|-------------------------|
| | Acid endopeptidase | Serine endopeptidase | Serine exopeptidase | Metallo exopeptidase (Zn^{2+}) | 2.6 | 4.7 | 45.55 | Vacuole | 3.5-4.0 | 35-40 |
| | | | | | 6.7 | 6.7 | 45.55 | Soluble | 3.8 | 60,000 |
| | | | | | | 6.0 | 61,000 | Not determined | 5.8 | 32,000-44,000 |
| | | | | | | 60 | 3.6 | Hg ²⁺ | 5.8 | Chymosin, etc. |
| | | | | | | 60 | 3.6 | EDTA | 5.8 | Pepsatin, etc. |
| | | | | | | 60 | 3.6 | Protein I ²⁻ | 5.8 | Protein I ²⁻ |
| | | | | | | 60 | 3.6 | Protein L ²⁻ | 5.8 | Protein L ²⁻ |
| | | | | | | 60 | 3.6 | Proteinase, etc. | 5.8 | Proteinase, etc. |
| | | | | | | 60 | 3.6 | Chymosin, etc. | 5.8 | Chymosin, etc. |
| | | | | | | 60 | 3.6 | Protein degradation | 5.8 | Protein degradation |
| | | | | | | 60 | 3.6 | Cellular role | 5.8 | Cellular role |

*Source: Based on data from Achshter and Wolf 1985.

EXHIBIT C

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



PCT

(43) International Publication Date
16 February 2006 (16.02.2006)

(10) International Publication Number
WO 2006/015627 A1

(51) International Patent Classification⁷: **A61K 7/48, 47/36**

(21) International Application Number:
PCT/EP2004/051793

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): **SYM-RISE GMBH & CO. KG [DE/DE]**; Mühlenfeldstrasse 1, 37603 Holzminden (DE).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **RÖDING, Joachim [DE/DE]**; Oberer Kirchweg 5, 79410 Badenweiler (DE).

(74) Agents: **STILKENBÖHMER, Uwe et al.**; Postfach 10 60 78, 28060 Bremen (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2006/015627 A1

(54) Title: **β-(1,3)-β-(1,4)-GLUCAN AS CARRIER FOR CHEMICAL SUBSTANCES**

(57) Abstract: Disclosed is the use of β-(1,3)-β-(1,4)-glucan (a) as carrier for carrying a chemical substance through the stratum corneum into deeper layers of the skin and/or (b) for improving the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.

Symrise GmbH & Co. KG
Mühlenfeldstraße 1, 37603 Holzminden

β -(1,3)- β -(1,4)-glucan as carrier for chemical substances

This invention primarily relates to the use of β -(1,3)- β -(1,4)-glucan (a) as carrier for carrying a chemical substance through the stratum corneum into deeper layers of the skin and/or (b) for improving the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.

- 2 -

Oat derived β -(1,3)- β -(1,4)-glucan is preferably used in the context of the present invention and is hereinafter also referred to as "Oat Glucan".

Corneocytes and intercellular lipids constitute the structure of the uppermost layer of the skin, the stratum corneum. It shares few properties with other biological barriers such as cellular membranes. The corneocytes are enclosed by a highly chemically resistant crosslinked envelope. The intercellular lipids are particularly suited to render the barrier impermeable. There are however, three putative pathways, i.e. appendageal (along hair follicles), transcellular, or intercellular. The latter pathway is considered the most prevailing one. Typically, in order to penetrate the stratum corneum to any appreciable extend, a molecule would have to be less than 1,000 Daltons in size, uncharged, and have to have a logP of between -1 and 3. (Schaefer, H. et al. (1996) Skin Barrier (Karger) pp. 43, pp. 116, pp. 151).

Gums are either hydrophobic or hydrophilic substances of molecular weight ranging from 10,000 to 50,000,000 Daltons. At low concentrations they are capable of forming gels, highly viscous suspensions or solutions when added to an appropriate solvent system. Gums commonly used in cosmetics, medicine or food include agar, algin, aloe, beta glucan, carrageenan, cellulose derivatives, gellan, guar gum, gum arabic, locust bean gum, pectin, pullulan, starches, xanthan (see Whistler, R.L. (1993) Industrial Gums: Polysaccharides and their derivatives Eds. WhistlerRL and BeMiller J.N. (Academic Press) pp2).

Glucans are homopolysaccharides consisting of glucose only. Glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochemical properties. However, different stereochemical conformations exist, since it is possible to link the glucose molecules in different ways. Hence, glucans are a diverse group of compounds with differing chemical, physical, and functional properties. The influence of the chemical structure of polysaccharides on their properties can be appreciated by comparing the common properties of some common homoglucans. Thus, Dextran, a (1,6)- α -glucan, with a small degree of branching, is extremely water soluble and non-gel forming. Amylose, a (1,4)- α -D-glucan, is sparingly soluble in water and can form rigid thermo-reversible gels. Cellulose, a (1,4)- β -D-glucan, is water insoluble and highly crystalline compared to other polysaccharides. Oat β -(1,3)- β -(1,4)-glucan is classified as a viscous gum, (see Wood, PJ 1 5 (1993) Oat Bran Ed PJ Wood (American Association of Cereal Chemists, Inc. St. Paul, MN)). Unmodified oat β -(1,3)- β -(1,4)-glucan forms highly


- 3 -

viscous solutions in water at concentrations >0.75 %wt. At concentrations >1.2 %wt. the solutions have the consistency of a thick hydrogel.

Cereal β -(1,3)- β -(1,4)-glucans are structural polysaccharides present in the cell wall of cereals like barley and oat, among others. Oat β -(1,3)- β -(1,4)-glucan, is recognised by the U.S. FDA as an agent that may aid the prevention of heart disease. In 1997, the FDA allowed oat products to make a health claim.

Glucans derived from yeast, fungi, certain bacteria and genetically engineered bacteria are of significantly different molecular structure and have different physical and chemical properties compared to oat glucan.

The structure of Oat Glucan indicating the 1,3- and 1-4 – linkages is as follows:



Oat Glucan is a water-soluble polysaccharide consisting of linear chains of glucose units with 1-3 and 1-4 linkages and has a mean molecular weight in the range of 500,000 - 1,000,000, typically of about 1 million.

Methods for formulating cereal beta glucan compositions that retard the natural gel forming properties of hydrocolloids and remain free flowing liquids are disclosed in WO 99/61480. This document provides for a simple and efficient method of formulating and producing stable solutions of beta-glucan. A biological, zwitterionic buffer is utilized during the purification process to retard gelation and/or precipitation of the beta-glucan upon cooling. The resulting beta-glucan preparation can be used directly or stored for future use.

Oat Glucan preferably used in the present invention can be obtained according to the process described in WO 99/61480. Such Oat Glucan is a liquid commercially available from Symrise Inc. or Symrise GmbH & Co. KG.

An aqueous 1%wt. solution of such Oat Glucan gives a viscous clear to opal product (at 25°C such a solution shows a viscosity of 500-1,000 mPas, measured with a rotational, shear-type viscosimeter such as the Brookfield Syncro-Lectric or the Haake Rotovisco).

- 4 -

EP 0 476 063 describes pharmaceutical compositions comprising a drug chemically bound to or being contained within whole beta-glucan particles. In particular a whole beta-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use, is taught. A drug is incorporated into a whole beta-glucan microparticle, and the combination is administered to an individual. The beta-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.

WO 96/14873 discloses a glucan composition containing a beta-1,3-glucan covalently attached to a bioactive agent. The beta-1,3-glucan is attached to the bioactive agent by means of a hydrolyzable covalent linkage to form a glucan/agent product. Also disclosed are methods relating to said product, including a method for the treatment of a pathogen capable of invading or colonizing phagocytic cells, and a method for delivering an antigen to a phagocytic cell.

US 5,676,967 discloses a wound dressing for covering a wound of the body, providing slow release of a combination of collagenic protein and oligosaccharide, enhancing vapor transmission from the wound, and enhancing healing. It comprises an aqueous combination of collagen and oligosaccharide coated on a mesh surface and dehydrated to a low moisture content. The mesh netting used has holes or openings, and the structure of the netting permits a solution of oligosaccharide such as glucan and a collagen to impregnate and fill the openings. The impregnated netting is then dehydrated and oligosaccharide and collagen are deposited and adhere to the fibers. An aqueous based mixture of the oligosaccharide and collagen for impregnating the mesh netting may contain about 1-10 percent oligosaccharide and 1-15 percent collagen. The mixture is applied to the mesh netting to substantially impregnate it. An aqueous-based solution of oat-derived beta-D-glucan and bovine collagen containing Type I and Type III collagens was prepared and the mesh netting impregnated therewith.

EP 1 046 394 is directed to compositions and their use for delivering compounds into a cell. In a preferred embodiment, the compositions comprise, in combination with the compound to be delivered, an organic halide, a targeting ligand, and a nuclear localization sequence, optionally in the presence of a carrier. In case the composition comprises a carrier or stabilizing materials, a large number of polymers may be used, *inter alia* glucans are suitable. The compositions are particularly suitable for the treatment of inflammatory diseases.

- 5 -

WO 01/87255 relates to an external application having enhanced skin absorbency of the active agents by using protease stabilized by beta-1,3-glucan branched with beta-1,6-linkage as an agent for enhancing the skin absorption. Stabilization of the protease is achieved by a chemical reaction in order to covalently bind the protease to the beta-glucan, the resulting product is then able to enhance the skin absorption of the active agents.

WO 03/054077 teaches the use of beta glucan as a film forming delivery system for controlled delivery of actives into an aqueous system, i.e. the mouth cavity. Cereal β -(1,3)- β -(1,4)-glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents. The β -(1,3)- β -(1,4)-glucan forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavours, fragrances. The technology has applications to essential oils and non-aqueous materials that are rendered deliverable by the β -(1,3)- β -(1,4)-glucan. The β -(1,3)- β -(1,4)-glucan films described may be consumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products.

There is no mention in prior art suggesting the use of β -(1,3)- β -(1,4)-glucan (and preferably Oat Glucan) as (a) as carrier for carrying a chemical substance through the stratum corneum into deeper layers of the skin and/or (b) for improving the penetration abilities of said chemical substance through the stratum corneum into deeper layers of the skin.

The present invention is based on the surprising finding that despite the general scientific teaching according to which in order to penetrate the stratum corneum to any appreciable extend, a molecule would have to be less than 1,000 Daltons in size, uncharged, and have to have a logP of between -1 and 3 (see above), β -(1,3)- β -(1,4)-glucan (and preferably Oat Glucan) is capable of penetrating the stratum corneum. It was likewise surprising that β -(1,3)- β -(1,4)-glucan (a) can act as a carrier for chemical substances which on its own cannot penetrate the stratum corneum and (b) can improve the penetration abilities of chemical substances through the stratum corneum into deeper layers of the skin. In particular it has been found that Oat Glucan can - despite its high molecular weight - penetrate through the stratum corneum into intact human skin. In addition Oat Glucan is able to form a complex with actives such as cosmetical, therapeutical and/or pharmaceutical actives without being covalently bound to these actives.

- 6 -

These findings are in particular of interest for the delivery of actives through the stratum corneum into the lower layers of the epidermis and beyond of intact, unharmed human skin (delivery for cosmetic purposes).

In the use according to the present invention, and likewise in methods and compositions according to the present invention, which will be discussed in more detail below, the following embodiments are preferred:

In preferred embodiments the β -(1,3)- β -(1,4)-glucan is not covalently bound to the chemical substance. This allows for an effective release of the chemical substance in the skin. Preferably, the chemical substance and β -(1,3)- β -(1,4)-glucan form a complex.

As mentioned before, the β -(1,3)- β -(1,4)-glucan is preferably prepared from oat. Oat Glucan can be prepared according to the methods described above.

The β -(1,3)- β -(1,4)-glucan preferably has a mean molecular weight of 10,000 to 5,000,000 g/mol, more preferably a mean molecular weight of 100,000 to 1,500,000 g/mol. In particular Oat Glucan having such mean molecular weight has surprisingly been found to be able to penetrate the stratum corneum.

The chemical substance is a preferably a cosmetical active agent.

The chemical substance (cosmetical active) is preferably a compound with a mean molecular weight ranging from 200 to 1,000,000. Such compound can be combined with β -(1,3)- β -(1,4)-glucan (preferably in an preferred embodiment as described above) and be carried through the stratum corneum to deeper layers of the skin.

The chemical substance favorably has a logP between -4 to 5.

The chemical substance (cosmetical active) is preferably a polymer, protein, or peptide or a mixture thereof, preferably a protein or peptide of either natural or synthetic origin. Such compounds regularly have very limited skin penetration abilities.

In preferred embodiments the chemical substance (cosmetical active) is selected from L-ascorbic acid, L-ascorbic acid derivatives, kojic acid, kojic acid derivatives, xanthin derivatives, bisabolol, vitamine E and vitamine E derivatives (e. g. tocopherolacetate).

The use is preferably non-therapeutic.

- 7 -

Further preferred embodiments of the use according to the present invention are described in the following parts of the description, including the examples, and in the attached claims.

The present inventions also relates to a method of delivering a chemical substance through the stratum corneum to deeper layers of the skin, the method comprising the following steps:

- mixing the chemical substance with an effective amount of β -(1,3)- β -(1,4)-glucan,
- topically applying the resulting mixture to the skin.

Regarding further preferred embodiments we particularly refer to the preferred embodiments for the use according to the present invention.

The present invention further relates to a topical composition comprising a mixture of (a) β -(1,3)- β -(1,4)-glucan and (b) at least one cosmetical, therapeutical and/or pharmaceutical active, said β -(1,3)- β -(1,4)-glucan and said active not being covalently bonded to each other, wherein the amount of β -(1,3)- β -(1,4)-glucan is chosen such that it (a) can act as carrier for carrying the chemical substance through the stratum corneum into deeper layers of the skin and/or (b) improves the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.

Again, regarding preferred embodiments we particularly refer to the preferred embodiments for the use according to the present invention.

Favourably, in the composition of the present invention the active is not a collagenic protein.

According to a related further aspect of the present invention β -(1,3)- β -(1,4)-glucan (favourably Oat Glucan) is used for producing a topical composition according to the present invention.

The present invention relates to the use of Oat Glucan as delivery agent for the delivery of one or more chemical substances like cosmetical, therapeutical and/or pharmaceutical actives through the stratum corneum into the epidermis and even into deeper layers of the skin.

In combinations of (and favourably complexes consisting of) Oat Glucan and actives, such as cosmetical, therapeutical and/or pharmaceutical actives, Oat Glucan can be considered a delivery agent for said actives and may be used for the delivery of said actives through the

stratum corneum into deeper layers of the skin. This is particularly an advantage when said complex is used in topical applications. For best results, the combination/complex is obtained by premixing or homogenizing Oat Glucan and active before subsequent processing and incorporation into a topical (cosmetic) composition.

Prefered is a mixture (preferably a complex) of Oat Glucan and active wherein the ratio of Oat Glucan to active is ranging from 1,000:1 to 1:1,000, preferably ranging from 100:1 to 1:100, even more preferred ranging from 30:1 to 1:30.

A mixture of β -(1,3)- β -(1,4)-glucan (preferably Oat Glucan) and active (or other chemical substance) as used according to the present invention preferably is incorporated into a topical (cosmetic) composition in an amount ranging from 0,005 to 10% by weight, more preferably 0,01 to 5% by weight, based on the total weight of the topical (cosmetic) composition.

Topical (cosmetic) compositions according to the present invention can comprise (cosmetic and/or dermatological) auxiliaries and additives, as are usually used in such preparations, e.g., sunscreens / uv-absorbers (e.g., organic or inorganic light filter substances, micropigments), preservatives, bactericides, fungicides, virucides, ingredients which have a cooling action, plant extracts, antiinflammatory active ingredients, substances which accelerate wound healing (e.g. chitin or chitosan and derivatives thereof), film-forming substances (e.g. polyvinylpyrrolidones or chitosan or derivatives thereof), customary antioxidants, vitamins (e.g. vitamin C and derivatives, tocopherols and derivatives, vitamin A and derivatives), 2-hydroxycarboxylic acids (e.g. citric acid, malic acid, L-, D- or dl-lactic acid), skin lighteners (e.g. kojic acid, hydroquinone or arbutine, ascorbic acid, ascorbic acid derivatives, hydroquinone, hydroquinone derivatives, sulfur-containing molecules, such as, for example, glutathione or cysteine or other synthetic or natural active ingredients for skin lightening, it being possible for the latter to be used also in the form of an extract from plants, such as, for example, bearberry extract and rice extract), skin colorants (e.g. walnut extracts or dihydroxyacetone), perfumes, fragrance compounds, antifoams, dyes, pigments which have a coloring action, thickeners, surface-active substances, emulsifiers, emollients, humectants and/or moisturizers (e.g. glycerol or urea), fats, oils, unsaturated fatty acids or derivatives thereof (e.g. linoleic acid, (a-linolenic acid, γ -linolenic acid or arachidic acid and the natural or synthetic esters thereof in each case), waxes or other customary constituents of a cosmetic or dermatological formulation, such as alcohols, polyols, polymers, foam

- 9 -

stabilizers, electrolytes, organic solvents, silicone derivatives or chelating agents (e.g., ethylenediaminetetraacetic acid and derivatives).

The amounts of (cosmetic and/or dermatological) auxiliaries or additives to be used in each case can easily be determined by simple exploratory experiments by the person skilled in the art, depending on the nature of the product in question.

The topical (cosmetic) composition according to the present invention can additionally comprise UVA and/or UVB filter substances. The total amount of UV filter substances preferably may be from 0.1 to 30% by weight, more preferably from 0.5 to 10% by weight, based on the total weight of the composition, giving, for example, sunscreens for skin and hair. Examples of UV filter substances which can be used are 3-benzylidene camphor derivatives (e.g., 3-(4-methylbenzylidene)-dl-camphor), amino-benzoic acid derivatives (e.g., 2-ethylhexyl 4-(N,N-dimethylamino)benzoate or methyl anthranilate), 4-methoxycinnamates (e.g., 2-ethylhexyl p-methoxycinnamate or isoamyl p-methoxycinnamate), benzophenones (e.g., 2-hydroxy-4-methoxybenzophenone), mono- or polysulphonated UV filters [e.g., 2-phenylbenzimidazole-5-sulphonic acid, sulisobenzones or 1,4-bis(benzimidazolyl)-benzene-4,4',6,6'-tetrasulphonic acid and 3,3'-(1,4-phenylenedimethylidene)-bis-(7,7-dimethyl-2-oxo-bicyclo-[2,2,1]heptane-1-methanesulphonic acid) and salts thereof], salicylates (e.g., 2-ethylhexyl salicylate or homomethyl salicylate), triazines (e.g., 2,4-bis-[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, bis-(2-ethylhexyl) 4,4'-([6-((1,1-dimethylethyl)-aminocarbonyl)phenylamino]-1,3,5-triazin-2,4-diyl]dimino)bisbenzoate), 2-cyanopropenoic acid derivatives (e.g., 2-ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate), dibenzoyl derivatives (e.g., 4-tert.-butyl-4'-methoxydibenzoylmethane), polymer-bonded UV filters (e.g., polymer of N-[2-(or 4)-(2-oxo-3-bomylidene)methyl]-benzylacrylamide) or pigments (e.g., titanium dioxides, zirconium dioxides, iron oxides, silicon dioxides, manganese oxides, aluminium oxides, cerium oxides or zinc oxides).

The lipid phase in the topical (cosmetic) compositions according to the present invention can advantageously be chosen from the following groups of substances: mineral oils (advantageously paraffin oil), mineral waxes, hydrocarbons (advantageously squalane or squalene), synthetic or semisynthetic triglyceride oils (e.g., triglycerides of capric or caprylic acid), natural oils (e.g., castor oil, olive oil, sunflower oil, soya oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, borage oil seed oil and the like), natural ester oils (e.g., jojoba oil), synthetic ester oils (preferably esters of saturated and/or unsaturated, linear and/or branched alkanecarboxylic acids carrying from 3 to 30 carbon

- 10 -

atoms with saturated and/or unsaturated, linear and/or branched alcohols having from 3 to 30 carbon atoms and esters of aromatic carboxylic acids with saturated and/or unsaturated, linear and/or branched alcohols having from 3 to 30 carbon atoms, in particular, chosen from the group consisting of isopropyl myristate, isopropyl stearate, isopropyl palmitate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl laurate, isoctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, and synthetic or natural mixtures of such esters), fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty alcohols with alcohols of low carbon number (e.g., with isopropanol, propylene glycol or glycerol) or esters of fatty alcohols with alcanoic acids of low carbon number or with fatty acids, alkyl benzoates (e.g., mixtures of n-dodecyl, n-tridecyl, n-tetradecyl and n-pentadecyl benzoate), and cyclic or linear silicone oils (such as, for example, dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes, and mixed forms thereof).

The aqueous phase of the topical (cosmetic) compositions according to the present invention optionally, advantageously comprises alcohols, diols or polyols of low carbon number, and ethers thereof, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ethers, propylene glycol monomethyl, monoethyl or monobutyl ethers, diethylene glycol monomethyl or monoethyl ethers and analogous products, and also alcohols of low carbon number, e.g., ethanol, isopropanol, 1,2-propanediol, glycerol, and also α- or β-hydroxy acids, preferably lactic acid, citric acid or salicylic acid, and also emulsifiers, which may be advantageously chosen from the group consisting of ionic, nonionic, polymeric, phosphate-containing and zwitterionic emulsifiers, and, in particular one or more thickeners, which may advantageously be chosen from the group consisting of silicon dioxide, aluminium silicates, such as, for example, bentonites, polysaccharides and derivatives thereof, e.g., hyaluronic acid, guar flour, xanthan gum, hydroxypropylmethylcellulose or allulose derivatives, particularly advantageously from the group of polyacrylates, preferably, a polyacrylate from the group of so-called Carbopol, in each case individually or in combination, or from the group of polyurethanes.

For use, the topical (cosmetic) compositions according to the present are applied to the skin and/or hair.

- 11 -

Examples

Unless indicated otherwise all figures and percentages given are by weight.

Oat Glucan as used in the Examples can be obtained according to the process described in WO 99/61480. Oat Glucan as used in the Examples is commercially available from Symrise Inc. or Symrise GmbH & Co. KG.

Example 1

Phacocell® was used for the Oat Glucan penetration study. In a pilot-study the method was adapted, methodical errors, like presence of fungi etc. were eliminated. The method was developed as to match actual *in vivo* conditions as best as possible, in view of the variability of the fluorescence staining technique.

1. Method

1.1 Skin specimens

Abdominal human skin was surgically removed and cut to size to fit the chamber. The skin sections were stored under liquid nitrogen and sterilized by gamma-radiation with 25 KGy overnight. This treatment destroys all fungi, which could interfere with the analysis. After radiation, the skin samples were defrosted and inspected macroscopically for integrity before use in order to avoid leaks. The skin specimen were inspected for leaks again after staining with fluorescent stain.

1.2 Target variables, preparations, dosage

The main goal of the study was to determine the glucan concentration on top of the skin and in the layers of the skin (stratum corneum, epidermis, dermis, and subcutis). The applied dosage of 5 mg/cm² corresponds realistic *in vivo* amounts. The fluorescence technique allows semi-quantitative results, which were determined from slides. The preparations were applied uniformly to the skin surface using a micro dose applicator (volume, graduation weight based).

- 12 -

1.3. Phacocell®

The Phacocell® cell has a chamber with the volume of 20 ml, filled with an acceptor medium, in which the active is well soluble. The medium was set at 36°C and circulated continuously. The chamber was kept free of air bubbles during filling in order to guarantee complete and uncompromised contact with the tissue. Pressure compensation, in and outside of the chamber and constant humidity was provided by ventilation. The skin specimen was conditioned with respect to surface temperature (32°C) and moisture content (65 RU corneometer units) via a ventilation channel. The desired conditioning was achieved by preheating the medium, by controlling the heating plate in the base of the chamber and by controlling the air tubes, and by adjusting the flow speed of the air. These parameters were constant during each of the series of experiments. The skin specimens from surgery were free of fat tissue. A macroscopic and physical inspection of the suitability of the skin specimen was carried out (before application pressure tested for leaks, and after 8 h by color detection for leaks). The area of application was 10 cm² for all samples. The skin specimen was supplied with nutrients via the uniformly circulating nutrient medium, which was in contact with the bottom surface of the skin sample. The skin temperature was monitored with temperature sensors, and the moisture content with a corneometer. The settings of the air flow across the skin's upper surface precluded hydration of the skin specimens and thus rendered the experimental conditions non-occlusive.

1.4. Fluorescence Microscopy

Sophisticated microscopes and numerous accessories have been developed based on the principals of fluorescence. Epi-fluorescence, or incident light fluorescence, has now become the method of choice in many applications. The phenomenon of fluorescence is based on a light emission that continues only during the absorption of the excitation light by a chromophore or other conjugated molecule, which is capable of emitting secondary fluorescence.

Excitation and Emission Fundamentals - fluorochromes have unique and characteristic spectra for absorption (usually similar to excitation) and emission. The visible emission spectra and the associated phenomena are utilized in fluorescence microscopy.

Light Sources - In order to generate enough excitation light intensity to furnish secondary fluorescence emission capable of detection, powerful light sources were used. These xenon

- 13 -

arc (burner) lamps, which produce high-intensity illumination was powerful enough to image faintly visible fluorescence specimens.

Filter Cubes - Microscope manufacturers (LEIKA) provide proprietary filter cubes that contain a combination of dichroic mirrors and filters capable of exciting fluorescent chromophores and diverting the resulting secondary fluorescence to the eyepieces or camera tube. A LEIKA fluorescence microscope was used with an exciter filter ranging between 400-500nm with a peak at 440nm and a barrier filter of 500-520nm for optimum results.

1.5. Skin Swab Samples

The skin swab samples were taken with cotton gauze swabs from the skin surface after 8 hours had elapsed: 1st and 3rd swab moistened with 0.2 ml 70% methanol / H₂O, 2nd and 4th swab dry.

1.6. Main Objective: Determination of Oat Glucan Penetration into the Skin

The presence of Oat Glucan in the stratum corneum and in the other skin tissues was detected by microscope. The cleaned skin samples of the Phacocell® chamber were separated with punch-biopsies and immediately deep frozen, cut into thin slices of 15 µm in width. The skin was cut against the penetratio grade, i.e. from the dermis towards the stratum corneum. The slices were air dried and not fixed by any fluid. Fixation with fluids can cause a dilution and/or displacement of Oat Glucan. The proceeding of fluorescence staining was developed by technical service of REMEL Industry, BACTIDROP™. Calcofluor White is recommended for use in qualitative procedures as a rapid, non-specific fluorochrome stain for the initial microscopic detection of fungal elements and can be used for the detection of Oat Glucan molecules as well. Calcofluor white is a non-specific fluorochrome with the ability to bind to cellulose and chitin. Upon excitation with longwave ultraviolet light, this compound functions to delineate the cell walls of cellulose-containing organisms.

1.7. Procedure: Use of BACTIDROP™

A fluorescent microscope with an exciter filter ranging between 400-500nm with a peak of 440nm and a barrier filter of 500-520nm is recommended for optimum results with calcofluor white.

1.8. Controls

- Untreated skin was subjected to the same regime in the Phacocell®- No fluorescence staining was detectable.

1.9. Data Processing - Quality Control The data were entered centrally into the computer (SAS Modul® / Oracle®), following checks for plausibility and quality. Statistical evaluation was carried out by the statistics software package SAS/Statistica®.

1.10 Results

Fluorescence - Densitometry

The detection of Oat Glucan in skin tissue after 8 hours indicates an uptake into the horny layer and the epidermis. The degree of fluorescent staining suggested that there were high concentrations of glucan in the horny layer and the epidermis. Levels detected in the dermis and subcutis were lower (Table 1). The different glucan concentrations among the tested samples (sample 1 = 5% Oat glucan, sample 2 = 50% Oat glucan) did not translate into proportional concentration in the tissue. The measurement and procedure of staining had an error of 2 - 3 % in tissue. Overall the results show the significant penetration of Oat Glucan into the epidermis.

TABLE 1: Detection of Oat Glucan in the different layers of the skin after 8 h

| | Sample 1 | | Sample 2 | | Control | |
|---------------------------|----------|-------|----------|-------|---------|-------|
| Mean Deposition | [%] | Stdv. | [%] | Stdv. | [%] | Stdv. |
| Stratum corneum | 8.7 | 1.2 | 12.8 | 1.9 | 0.6 | 0.2 |
| Lower layers of Epidermis | 5.9 | 1.3 | 11.6 | 2.0 | 0.8 | 0.2 |
| Dermis | 2.4 | 0.5 | 4.1 | 1.1 | 0.6 | 0.1 |
| Subcutis | 1.4 | 0.5 | 1.5 | 0.4 | 0.9 | 0.1 |

- 15 -

| | | | | | | |
|------------|------|-----|------|-----|--|--|
| | | | | | | |
| % recovery | 18.4 | 1.7 | 29.9 | 3.0 | | |

Stdv: standard deviation

Example 2

Lotion (W/O)

| Phase | Ingredient | INCI | %wt. |
|-------|--------------------------------------|--|-------|
| A | Lanette O | Cetearyl Alcohol | 1.80 |
| | Dracorin 100 s.e.P. | Glyceryl Stearate, PEG-100 Stearate | 6.00 |
| | Paraffin Oil (White Oil) | Mineral Oil | 5.00 |
| | Cetiol 868 | Octyl Stearate | 2.00 |
| | Cetiol J600 | Oleyl Erucate | 2.00 |
| | Stearic Acid (Stearin L2 S.M. Luxus) | Stearic Acid | 1.00 |
| B | Propylen Glycol | Propylene Glycol | 3.50 |
| | Water | Aqua | 73.00 |
| | Dragocid liquid | Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Iso-butylparaben | 0.70 |
| C | β-Glucan/Whey Extract (25:1) | β-Glucan + Whey Extract (25:1) | 4.8 |
| D | Perfume oil | Parfum (Fragrance) | 0.2 |

- 16 -

Preparation method

Heat phase A and phase B separately to 80 °C. Add B to A and homogenize for about 5 min. Homogenize phase C by mixing, by weight, 25 parts Oat Glucan and one part Whey Extract at ambient temperature for about 2 minutes. Cool down the mixture of parts A and B to about 40 °C, then add homogenized phase C and subsequently phase D. After homogenization of the topical composition cool down to ambient temperature.

- 17 -

Claims

1. Use of β -(1,3)- β -(1,4)-glucan (a) as carrier for carrying a chemical substance through the stratum corneum into deeper layers of the skin and/or (b) for improving the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.
2. Use according to claim 1, wherein the β -(1,3)- β -(1,4)-glucan is not covalently bound to the chemical substance.
3. Use according to claim 1 or 2, wherein the β -(1,3)- β -(1,4)-glucan is prepared from oat.
4. Use according to any preceding claim, wherein the β -(1,3)- β -(1,4)-glucan has a mean molecular weight of 10,000 to 5,000,000.
5. Use according to any preceding claim, wherein the β -(1,3)- β -(1,4)-glucan has a mean molecular weight of 100,000 to 1,500,000.
6. Use according to any preceding claim, wherein the chemical substance is a cosmetical active agent.
7. Use according to any the preceding claim, wherein the chemical substance is a compound with a mean molecular weight ranging from 200 to 1,000,000.
8. Use according to claim 7, wherein the chemical substance has a logP between -4 to 5.
9. Use according to any preceding claim, wherein the substance is a polymer, protein, or peptide or a mixture thereof.
10. Use according to any of claims 4 - 7, wherein the substance is selected from L-ascorbic acid, L-ascorbic acid derivatives, kojic acid, kojic acid derivatives, xanthin derivatives, bisabolol, vitamine E and vitamine E derivatives.
11. Use according to any preceding claim, wherein the use is non-therapeutic.

- 18 -

12. Method of delivering a chemical substance through the stratum corneum to deeper layers of the skin, comprising the following steps:

- mixing the chemical substance with an effective amount of β -(1,3)- β -(1,4)-glucan,
- topically applying the resulting mixture to the skin.

13. Topical composition comprising a mixture of (a) β -(1,3)- β -(1,4)-glucan and (b) at least one cosmetical, therapeutical and/or pharmaceutical active, said β -(1,3)- β -(1,4)-glucan and said active not being covalently bonded to each other, wherein the amount of β -(1,3)- β -(1,4)-glucan is chosen such that it (a) can act as carrier for carrying the chemical substance through the stratum corneum into deeper layers of the skin and/or (b) improves the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.

14. Topical composition according to claim 13, wherein the active is not a collagenic protein.

15. Use of β -(1,3)- β -(1,4)-glucan for producing a topical composition according to any of claims 13 or 14.

INTERNATIONAL SEARCH REPORT

PCT/EP2004/051793

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K7/48 A61K47/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 01/87255 A (PACIFIC CORPORATION; SHIN, EUI, SEOK; LEE, JANG, YOUNG; KIM, MU, SUNG;) 22 November 2001 (2001-11-22) cited in the application claims; examples | 1-15 |
| E | WO 2004/096242 A (CEAPRO INC; REDMOND, MARK, J; FIELDER, DAVID, A) 11 November 2004 (2004-11-11) page 23, paragraph 4 page 27, line 4 - line 6; example 2 | 1-15 |
| X | WO 99/21531 A (BRENNEN MEDICAL, INC) 6 May 1999 (1999-05-06) claims; examples | 13-15 |

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

23 May 2005

10/06/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Minas, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| X | WO 01/74300 A (BRENNEN MEDICAL, INC) 11 October 2001 (2001-10-11) page 7, line 17 - page 8, last line ; claims ----- | 13-15 |
| X | WO 03/054077 A (CEAPRO INC; REDMOND, MARK, J; FIELDER, DAVID, A) 3 July 2003 (2003-07-03) cited in the application examples 4,6 ----- | 13-15 |
| A | DATABASE WPI Section Ch, Week 200340 Derwent Publications Ltd., London, GB; Class A96, AN 2003-423910 XP002329032 & JP 2002 275046 A (KANEBO LTD) 25 September 2002 (2002-09-25) abstract ----- | 1-15 |
| A | WO 96/14873 A (SRI INTERNATIONAL) 23 May 1996 (1996-05-23) cited in the application claims ----- | 1-15 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/051793

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-10 and 12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051793

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|---|------------------|----------------------------------|---|--|--|
| WO 0187255 | A | 22-11-2001 | AU CN EP JP WO US | 5887601 A 1457253 A 1282393 A1 2004507458 T 0187255 A1 2004022753 A1 | | 26-11-2001 19-11-2003 12-02-2003 11-03-2004 22-11-2001 05-02-2004 |
| WO 2004096242 | A | 11-11-2004 | WO WO WO | 2004096242 A1 2004096862 A2 2004108103 A1 | | 11-11-2004 11-11-2004 16-12-2004 |
| WO 9921531 | A | 06-05-1999 | US CA EP JP WO US | 5980918 A 2304815 A1 1024784 A1 2001520982 T 9921531 A1 6168799 B1 | | 09-11-1999 06-05-1999 09-08-2000 06-11-2001 06-05-1999 02-01-2001 |
| WO 0174300 | A | 11-10-2001 | AU EP WO US | 5087501 A 1267795 A1 0174300 A1 2004005364 A1 | | 15-10-2001 02-01-2003 11-10-2001 08-01-2004 |
| WO 03054077 | A | 03-07-2003 | AU WO CA EP US | 2002347165 A1 03054077 A1 2467378 A1 1453909 A1 2005031674 A1 | | 09-07-2003 03-07-2003 03-07-2003 08-09-2004 10-02-2005 |
| JP 2002275046 | A | 25-09-2002 | NONE | | | |
| WO 9614873 | A | 23-05-1996 | WO | 9614873 A2 | | 23-05-1996 |